Gilead Sciences, Inc. (GILD)

Basic

  • Market Cap

    $97.61B

  • EV

    $113.39B

  • Shares Out

    1,246.04M

  • Revenue

    $27.39B

  • Employees

    17,000

Margins

  • Gross

    78.81%

  • EBITDA

    42.85%

  • Operating

    33.61%

  • Pre-Tax

    26.42%

  • Net

    21.45%

  • FCF

    28.67%

Returns (5Yr Avg)

  • ROA

    9.99%

  • ROE

    20.87%

  • ROCE

    19.18%

  • ROIC

    16.04%

Valuation (TTM)

  • P/E

    —

  • P/B

    —

  • EV/Sales

    —

  • EV/EBITDA

    —

  • EV/FCF

    —

  • EV/Gross Profit

    —

Valuation (NTM)

  • Price Target

    $90.39

  • P/E

    —

  • EV/Sales

    —

  • EV/EBITDA

    —

  • EV/FCF

    —

Per Share

  • Rev

    $21.9

  • Earnings (Dil)

    $4.67

  • FCF

    $6.23

  • Book Value

    $17.89

Growth (CAGR)

  • Rev 3Yr

    5.77%

  • Rev 5Yr

    4.22%

  • Rev 10Yr

    9.97%

  • Dil EPS 3Yr

    66.77%

  • Dil EPS 5Yr

    31.11%

  • Dil EPS 10Yr

    9.9%

  • Rev Fwd 2Yr

    0.6%

  • EBITDA Fwd 2Yr

    -0.77%

  • EPS Fwd 2Yr

    -0.01%

  • EPS LT Growth Est

    11.7%

Dividends

  • Yield

    —

  • Payout

    63.42%

  • DPS

    $2.98

  • DPS Growth 3Yr

    3.73%

  • DPS Growth 5Yr

    5.97%

  • DPS Growth 10Yr

    —

  • DPS Growth Fwd 2Yr

    4.35%

Select a metric from the list below to chart it

Dec '13
Dec '15
Dec '17
Dec '19
Dec '21
LTM
Metric
Dec '13
Dec '14
Dec '15
Dec '16
Dec '17
Dec '18
Dec '19
Dec '20
Dec '21
Dec '22
LTM

Total Revenues

22,127.0

22,449.0

24,689.0

27,305.0

27,281.0

27,391.0

Total Revenues % Chg.

-15.2%

1.5%

10.0%

10.6%

-0.1%

0.9%

Cost of Goods Sold, Total

4,853.0

4,675.0

3,691.0

5,526.0

5,657.0

5,804.0

Gross Profit

17,274.0

17,774.0

20,998.0

21,779.0

21,624.0

21,587.0

Selling General & Admin Expenses, Total

4,056.0

4,381.0

5,112.0

5,246.0

5,673.0

6,502.0

R&D Expenses

3,920.0

4,055.0

4,927.0

4,601.0

4,977.0

5,880.0

Other Operating Expenses, Total

7,976.0

8,436.0

10,039.0

9,847.0

10,650.0

12,382.0

Operating Income

9,298.0

9,338.0

10,959.0

11,932.0

10,974.0

9,205.0

Interest Expense, Total

-1,077.0

-995.0

-984.0

-1,001.0

-935.0

-918.0

Net Interest Expenses

-1,077.0

-995.0

-984.0

-1,001.0

-935.0

-918.0

Currency Exchange Gains (Loss)

-2.0

22.0

—

-23.0

-21.0

—

Other Non Operating Income (Expenses)

563.0

605.0

244.0

-6.0

97.0

311.0

EBT, Excl. Unusual Items

8,782.0

8,970.0

10,219.0

10,902.0

10,115.0

8,598.0

Merger & Related Restructuring Charges

—

—

-920.0

—

—

—

Gain (Loss) On Sale Of Investments

115.0

1,241.0

-1,662.0

-610.0

-657.0

-417.0

Asset Writedown

—

—

—

—

—

—

In Process R&D Expenses

-1,098.0

-5,051.0

-5,968.0

-939.0

-3,644.0

-966.0

Legal Settlements

—

—

—

-1,075.0

—

—

Other Unusual Items

—

—

—

—

—

22.0

EBT, Incl. Unusual Items

7,799.0

5,160.0

1,669.0

8,278.0

5,814.0

7,237.0

Income Tax Expense

2,339.0

-204.0

1,580.0

2,077.0

1,248.0

1,408.0

Earnings From Continuing Operations

5,460.0

5,364.0

89.0

6,201.0

4,566.0

5,829.0

Minority Interest

-5.0

22.0

34.0

24.0

26.0

47.0

Net Income

5,455.0

5,386.0

123.0

6,225.0

4,592.0

5,876.0

Net Income to Common Incl Extra Items

5,455.0

5,386.0

123.0

6,225.0

4,592.0

5,876.0

Net Income to Common Excl. Extra Items

5,455.0

5,386.0

123.0

6,225.0

4,592.0

5,876.0

Total Shares Outstanding

1,282.0

1,266.0

1,254.0

1,254.0

1,247.0

1,247.0

Weighted Avg. Shares Outstanding

1,298.0

1,270.0

1,257.0

1,256.0

1,255.0

1,250.5

Weighted Avg. Shares Outstanding Dil

1,308.0

1,277.0

1,263.0

1,262.0

1,262.0

1,260.5

EPS

4.2

4.2

0.1

5.0

3.7

4.7

EPS Diluted

4.2

4.2

0.1

4.9

3.6

4.7

EBITDA

10,727.0

10,742.0

12,439.0

13,982.0

13,077.0

11,738.0